JP2010530438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530438A5 JP2010530438A5 JP2010513369A JP2010513369A JP2010530438A5 JP 2010530438 A5 JP2010530438 A5 JP 2010530438A5 JP 2010513369 A JP2010513369 A JP 2010513369A JP 2010513369 A JP2010513369 A JP 2010513369A JP 2010530438 A5 JP2010530438 A5 JP 2010530438A5
- Authority
- JP
- Japan
- Prior art keywords
- quinazoline
- carboxamide
- amino
- dichloro
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- -1 O (CR 2 ) q R 4 Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 102000000503 Collagen Type II Human genes 0.000 claims 2
- 108010041390 Collagen Type II Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000009386 Experimental Arthritis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000024799 Thyroid disease Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000021510 thyroid gland disease Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- UINCOVQQBKMABV-UHFFFAOYSA-N 4-[(2,4-dimethoxyphenyl)methylamino]-n-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=C(C(=O)NC=3C(=CC=C(NC(=O)C=4C=C(C=CC=4)C(F)(F)F)C=3)C)C=CC=C12 UINCOVQQBKMABV-UHFFFAOYSA-N 0.000 claims 1
- AVPZRQOWJMIECH-UHFFFAOYSA-N 4-amino-n-(2,6-dichloro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl AVPZRQOWJMIECH-UHFFFAOYSA-N 0.000 claims 1
- HIMKYXREQLEWMQ-UHFFFAOYSA-N 4-amino-n-(2,6-dichloro-3-cyano-5-methoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(C#N)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl HIMKYXREQLEWMQ-UHFFFAOYSA-N 0.000 claims 1
- WSTJETSUIZMOIF-UHFFFAOYSA-N 4-amino-n-(2,6-difluoro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(F)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1F WSTJETSUIZMOIF-UHFFFAOYSA-N 0.000 claims 1
- LTLHWUBPWLYYSN-UHFFFAOYSA-N 4-amino-n-(2-bromo-6-chloro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Br)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl LTLHWUBPWLYYSN-UHFFFAOYSA-N 0.000 claims 1
- SPWTVSNTAGFMHW-UHFFFAOYSA-N 4-amino-n-(2-chloro-3,5-dimethoxy-6-methylphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1C SPWTVSNTAGFMHW-UHFFFAOYSA-N 0.000 claims 1
- CHOJUHJYFAYISK-UHFFFAOYSA-N 4-amino-n-(2-chloro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=CC(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl CHOJUHJYFAYISK-UHFFFAOYSA-N 0.000 claims 1
- CGAVPBNRRTURCI-UHFFFAOYSA-N 4-amino-n-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1F CGAVPBNRRTURCI-UHFFFAOYSA-N 0.000 claims 1
- BRPQFUCXCWSPCI-UHFFFAOYSA-N 4-amino-n-(2-methylnaphthalen-1-yl)quinazoline-8-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CC=CC4=CC=C3C)=CC=CC2=C1N BRPQFUCXCWSPCI-UHFFFAOYSA-N 0.000 claims 1
- LQDXGMBFIYCGJQ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(cyclopropylcarbamoyl)-5-ethoxyphenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OCC)=CC=1C(=O)NC1CC1 LQDXGMBFIYCGJQ-UHFFFAOYSA-N 0.000 claims 1
- OVAUJQPLCIGAFU-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(cyclopropylcarbamoyl)-5-fluorophenyl]quinazoline-8-carboxamide Chemical compound C1=CC=C2C(N)=NC=NC2=C1C(=O)NC(C=1Cl)=C(Cl)C(F)=CC=1C(=O)NC1CC1 OVAUJQPLCIGAFU-UHFFFAOYSA-N 0.000 claims 1
- OUKLJJSDBADJHE-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(cyclopropylcarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NC1CC1 OUKLJJSDBADJHE-UHFFFAOYSA-N 0.000 claims 1
- OQXGBXHTPMAGKI-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(cyclopropylmethylcarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NCC1CC1 OQXGBXHTPMAGKI-UHFFFAOYSA-N 0.000 claims 1
- JDAPUBNMZXUCDJ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(dimethylcarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound COC1=CC(C(=O)N(C)C)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl JDAPUBNMZXUCDJ-UHFFFAOYSA-N 0.000 claims 1
- RATUYKSQHCLFTJ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(ethoxycarbamoyl)-5-fluorophenyl]quinazoline-8-carboxamide Chemical compound CCONC(=O)C1=CC(F)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl RATUYKSQHCLFTJ-UHFFFAOYSA-N 0.000 claims 1
- SWHJPMMJNKGTBR-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(ethoxycarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound CCONC(=O)C1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl SWHJPMMJNKGTBR-UHFFFAOYSA-N 0.000 claims 1
- GBOXLCTWINDHBP-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(ethylcarbamoyl)-5-fluorophenyl]quinazoline-8-carboxamide Chemical compound CCNC(=O)C1=CC(F)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl GBOXLCTWINDHBP-UHFFFAOYSA-N 0.000 claims 1
- IBWOCLVQLGBCMP-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(ethylcarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound CCNC(=O)C1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl IBWOCLVQLGBCMP-UHFFFAOYSA-N 0.000 claims 1
- VQZXLDFQVUWCPY-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-ethoxy-5-(ethoxycarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound CCONC(=O)C1=CC(OCC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl VQZXLDFQVUWCPY-UHFFFAOYSA-N 0.000 claims 1
- KQQUOLDEUSAZJQ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-ethoxy-5-(ethylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound CCNC(=O)C1=CC(OCC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl KQQUOLDEUSAZJQ-UHFFFAOYSA-N 0.000 claims 1
- FNWPSDWHVXMUPD-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-methoxy-5-(phenylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NC1=CC=CC=C1 FNWPSDWHVXMUPD-UHFFFAOYSA-N 0.000 claims 1
- MVHVNNPMNKVHJK-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-methoxy-5-(propylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound CCCNC(=O)C1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl MVHVNNPMNKVHJK-UHFFFAOYSA-N 0.000 claims 1
- LZPIJUSWLNETDB-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-methoxy-5-(pyridin-2-ylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NC1=CC=CC=N1 LZPIJUSWLNETDB-UHFFFAOYSA-N 0.000 claims 1
- XSIVHMVKGDOVQZ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-methoxy-5-(pyridin-3-ylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NC1=CC=CN=C1 XSIVHMVKGDOVQZ-UHFFFAOYSA-N 0.000 claims 1
- KRGCJHVGTOJSMD-UHFFFAOYSA-N 4-amino-n-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]quinazoline-8-carboxamide Chemical compound C1=C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 KRGCJHVGTOJSMD-UHFFFAOYSA-N 0.000 claims 1
- JPIDPKIRDNEUIY-UHFFFAOYSA-N 4-amino-n-[3-(butylcarbamoyl)-2,6-dichloro-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound CCCCNC(=O)C1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl JPIDPKIRDNEUIY-UHFFFAOYSA-N 0.000 claims 1
- SKPWWMGEZMVQLO-UHFFFAOYSA-N 4-chloro-n-(2,6-dichloro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(Cl)=C3C=CC=2)=C1Cl SKPWWMGEZMVQLO-UHFFFAOYSA-N 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- OUYJFMALBOPXOP-UHFFFAOYSA-N n-(2,6-dichloro-3,5-dimethoxyphenyl)-4-(pyridin-2-ylamino)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(NC=4N=CC=CC=4)=C3C=CC=2)=C1Cl OUYJFMALBOPXOP-UHFFFAOYSA-N 0.000 claims 1
- YVRUTCUMEVXMAK-UHFFFAOYSA-N n-(2,6-dichloro-3,5-dimethoxyphenyl)-4-[[5-(morpholin-4-ylmethyl)pyridin-2-yl]amino]quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(NC=4N=CC(CN5CCOCC5)=CC=4)=C3C=CC=2)=C1Cl YVRUTCUMEVXMAK-UHFFFAOYSA-N 0.000 claims 1
- FABFTFOSZVAQLN-UHFFFAOYSA-N n-[3-[(1-ethylpyrrolidin-2-yl)methoxy]-5-(trifluoromethyl)phenyl]-4-methoxyquinazoline-8-carboxamide Chemical compound CCN1CCCC1COC1=CC(NC(=O)C=2C3=NC=NC(OC)=C3C=CC=2)=CC(C(F)(F)F)=C1 FABFTFOSZVAQLN-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 0 C*=C(CN(C)*)C(N)=C(*)C(C)=NC=C Chemical compound C*=C(CN(C)*)C(N)=C(*)C(C)=NC=C 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94541007P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/067290 WO2008157575A1 (en) | 2007-06-21 | 2008-06-18 | Protein kinase inhibitors and methods for using thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530438A JP2010530438A (ja) | 2010-09-09 |
| JP2010530438A5 true JP2010530438A5 (enExample) | 2011-08-04 |
Family
ID=39682516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513369A Pending JP2010530438A (ja) | 2007-06-21 | 2008-06-18 | プロテインキナーゼ阻害剤およびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110053932A1 (enExample) |
| EP (1) | EP2170842A1 (enExample) |
| JP (1) | JP2010530438A (enExample) |
| KR (1) | KR20100035635A (enExample) |
| CN (1) | CN101687821A (enExample) |
| AU (1) | AU2008265843B2 (enExample) |
| BR (1) | BRPI0813216A2 (enExample) |
| CA (1) | CA2691100A1 (enExample) |
| EA (1) | EA201000003A1 (enExample) |
| MX (1) | MX2009013781A (enExample) |
| WO (1) | WO2008157575A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101641339B (zh) | 2007-02-01 | 2013-07-17 | 雷斯韦洛吉克斯公司 | 用于预防和治疗心血管疾病的化合物 |
| CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| CN102149712A (zh) * | 2008-02-29 | 2011-08-10 | 阵列生物制药公司 | 吡唑并[3，4-b]吡啶Raf抑制剂 |
| ES2392482T3 (es) * | 2008-02-29 | 2012-12-11 | Array Biopharma, Inc. | Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF |
| WO2009111280A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| AU2010224523B2 (en) | 2009-03-18 | 2014-05-08 | Resverlogix Corp. | Novel anti-inflammatory agents |
| MX374414B (es) | 2009-04-22 | 2025-03-06 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
| EP2937345B1 (en) * | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| EP2576566B1 (en) | 2010-05-28 | 2015-10-28 | Merck Sharp & Dohme B.V. | Thieno(2,3b)pyrazine compounds as b-raf inhibitors |
| WO2012037155A2 (en) * | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US10321419B2 (en) | 2011-08-10 | 2019-06-11 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| KR101967721B1 (ko) | 2011-08-10 | 2019-04-10 | 삼성전자 주식회사 | 무선 통신 시스템에서 확장 접속 차단 적용 방법 및 장치 |
| EP3429307B1 (en) | 2011-08-10 | 2022-06-15 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| KR102247818B1 (ko) | 2011-08-10 | 2021-05-04 | 삼성전자 주식회사 | 이동통신 시스템에서 복수의 캐리어를 이용해서 데이터를 전송하는 방법 및 장치 |
| IN2014KN00763A (enExample) | 2011-10-05 | 2015-10-02 | Samsung Electronics Co Ltd | |
| WO2013051853A1 (en) | 2011-10-05 | 2013-04-11 | Samsung Electronics Co., Ltd. | Method and apparatus for selecting neighbor cells in mobile communication system |
| IN2014KN00783A (enExample) | 2011-10-10 | 2015-10-02 | Samsung Electronics Co Ltd | |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| JP6307087B2 (ja) * | 2012-10-15 | 2018-04-04 | レスバーロジックス コーポレイション | ベンズアミド化合物の合成に有用な化合物 |
| EP2964260A2 (en) | 2013-03-06 | 2016-01-13 | F. Hoffmann-La Roche AG | Methods of treating and preventing cancer drug resistance |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| JP2017517552A (ja) | 2014-06-13 | 2017-06-29 | ジェネンテック， インコーポレイテッド | 抗癌剤耐性の治療及び防止方法 |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| MX394094B (es) | 2014-11-06 | 2025-03-24 | Bial R&D Invest S A | PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS. |
| US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| CN107530356A (zh) | 2015-03-13 | 2018-01-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| JP7034935B2 (ja) | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| MX2018012211A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
| JP7046827B2 (ja) | 2016-04-06 | 2022-04-04 | リソソーマル・セラピューティクス・インコーポレイテッド | イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| WO2017192929A1 (en) * | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| AU2019413694B2 (en) | 2018-12-28 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN112979615B (zh) * | 2019-12-17 | 2024-08-09 | 上海医药集团股份有限公司 | 一种喹唑啉脲类化合物、其制备方法、制备中间体、药物组合物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7031500A (en) * | 1999-09-23 | 2001-04-24 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| EE200200715A (et) * | 2000-06-28 | 2004-08-16 | Astrazeneca Ab | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena |
| AU2003270199A1 (en) * | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| CA2564175A1 (en) * | 2004-04-28 | 2005-11-10 | Arrow Therapeutics Limited | Chemical compounds |
-
2008
- 2008-06-18 EA EA201000003A patent/EA201000003A1/ru unknown
- 2008-06-18 EP EP08771318A patent/EP2170842A1/en not_active Withdrawn
- 2008-06-18 CN CN200880021088A patent/CN101687821A/zh active Pending
- 2008-06-18 CA CA2691100A patent/CA2691100A1/en not_active Abandoned
- 2008-06-18 MX MX2009013781A patent/MX2009013781A/es active IP Right Grant
- 2008-06-18 US US12/665,894 patent/US20110053932A1/en not_active Abandoned
- 2008-06-18 AU AU2008265843A patent/AU2008265843B2/en not_active Expired - Fee Related
- 2008-06-18 BR BRPI0813216-0A2A patent/BRPI0813216A2/pt not_active IP Right Cessation
- 2008-06-18 WO PCT/US2008/067290 patent/WO2008157575A1/en not_active Ceased
- 2008-06-18 KR KR1020097026460A patent/KR20100035635A/ko not_active Withdrawn
- 2008-06-18 JP JP2010513369A patent/JP2010530438A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530438A5 (enExample) | ||
| RU2019136279A (ru) | C5 -Анилинохиназолиновые соединения и их использование в лечении рака | |
| JP2010510242A5 (enExample) | ||
| JP2008528468A5 (enExample) | ||
| RU2012136451A (ru) | Композиции и способы улучшения активности протеасомы | |
| JP2011514894A5 (enExample) | ||
| JP2010540452A5 (enExample) | ||
| JP2010530432A5 (enExample) | ||
| RU2008141434A (ru) | Пиразолы как 11-бета-hsd-1 | |
| JP6319436B2 (ja) | ２−アシルアミノチアゾール誘導体またはその塩 | |
| JP2010506918A5 (enExample) | ||
| RU2009119290A (ru) | Производные гидантоина, используемые в качестве ингибиторов ммр | |
| JP2007519754A5 (enExample) | ||
| JP2007535551A5 (enExample) | ||
| RU2010115574A (ru) | Замещенные амиды, фармацевтическая композиция на их основе, способ лечения заболевания, чувствительного к btk, способ повышения чувствительности раковых клеток к химиотерапии, способ уменьшения ошибок при приеме лекарства и улучшения соблюдения схемы лечения, способ ингибирования гидролиза атф, способ определения присутствия btk в образце и способ ингибирования активности в-клеток | |
| ME02696B (me) | MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI | |
| RU2008108984A (ru) | Терапевтический агент от диабета | |
| NZ601408A (en) | Novel 3-hydroxy-5-arylisothiazole derivative | |
| JP2016506964A5 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| JP2013503901A5 (enExample) | ||
| RU2012129737A (ru) | Замещенные бензамидные производные | |
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| RU2015144653A (ru) | Противовирусные соединения и их применения | |
| CA2566945A1 (en) | Pyrazole derivatives, compositions containing such compounds and methods of use |